Volume 27, Issue 5 (10-2019)                   JSSU 2019, 27(5): 1505-1515 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Akhondi-Meybodi M. New treatment of hepatitis C (Direct Acting Antiviral). JSSU. 2019; 27 (5) :1505-1515
URL: http://jssu.ssu.ac.ir/article-1-4743-en.html
Abstract:   (135 Views)
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention, recently in Iran new drug direct Acting agent (DAA) was developed that may be equivalent to original drugs that will hope to treat  HCV and eliminated HCV in future
Full-Text [PDF 873 kb]   (44 Downloads)    
Type of Study: Review article | Subject: Infectious Diseases
Received: 2018/11/17 | Accepted: 2019/01/19 | Published: 2019/10/9

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2019 All Rights Reserved | SSU_Journals

Designed & Developed by : Yektaweb